title: Phenol procedure for pilonidal sinus disease and risk factors for treatment failure.
abstract: BACKGROUND
  The present study was designed to evaluate the results of phenolization for pilonidal sinus disease and the risk factors for treatment failure.
  
  
  METHODS
  Between June 2005 and July 2009, 76 consecutive patients with nonrecurrent sacrococcygeal pilonidal sinus were treated with a phenol treatment and included in the study. The clinical (age, sex, story of treatment for abscess formation, and comorbidity), operative (localization and number of sinus openings and volume of cavity), and follow-up data (healing time, time off work, postoperative complications, morbidity, and number of phenolization sessions) of the patients was recorded. Gender, age, history of abscess drainage, number of sinus openings, localization of sinus openings, volume of cavity, and the number of phenolization sessions were analyzed as risk factors for treatment failure.
  
  
  RESULTS
  The overall success rate was 67% (51 of 76 patients). The mean time to complete healing was 16 days (range, 10-45). The time off work was 0 days. Age and gender were not found to be risk factors for treatment failure (P > .05 and P > .05, respectively). Patients with a history of abscess drainage and more than 3 sinus openings had a significantly higher risk of treatment failure (P = .001 and P = .046, respectively). There was no difference between the localization of sinus openings and treatment failure (P > .05). There were statistically significant differences between treatment failure and both the cavity volume and number of phenolization sessions (P = .016 and P = .001, respectively). Patients were followed up for a mean period of 25 months (range, 13-48). One patient (2%) showed recurrence.
  
  
  CONCLUSIONS
  With an early return to work and low rates of complications and recurrence, phenolization is a simple outpatient procedure for the treatment of pilonidal sinus disease in selected patients.
authors: Department of General Surgery, Medical Faculty of Mersin University, Mersin, Turkey. dahmetdag@yahoo.com
authors: Ahmet
authors: A
authors: Dag
authors: Tahsin
authors: T
authors: Colak
authors: Ozgur
authors: O
authors: Turkmenoglu
authors: Alper
authors: A
authors: Sozutek
authors: Ramazan
authors: R
authors: Gundogdu
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D019800:Phenol / Q000627:therapeutic use*; D010864:Pilonidal Sinus / Q000628:therapy*; D012307:Risk Factors; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D012597:Sclerosing Solutions; D019800:Phenol